An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia

L Strilchuk, G Tocci, F Fogacci… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …

An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.

L Strilchuk, G Tocci, F Fogacci, A Cicero - EXPERT OPINION ON …, 2020 - cris.unibo.it
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …

An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia

L Strilchuk, G Tocci, F Fogacci… - Expert opinion on …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …

An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.

L Strilchuk, G Tocci, F Fogacci… - Expert Opinion on …, 2020 - europepmc.org
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …

[引用][C] An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia

L Strilchuk, G Tocci, F Fogacci, AFG Cicero - Expert Opinion on …, 2020 - elibrary.ru

An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia

L Strilchuk, G Tocci, F Fogacci… - EXPERT OPINION ON …, 2020 - iris.uniroma1.it
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …